Osteonecrosis of the jaws and bevacizumab therapy: A case report

International Journal of Immunopathology and Pharmacology

Volumn 25, Issue 3, 2012, Pages 789-791

  Brunamonti Binello, P ^a   Bandelloni, R ^a   Labanca, M ^b   Buffoli, B ^c   Rezzani, R ^c   Rodella, L F ^c  

^a GALLIERA HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Bevacizumab; Jaws; Osteonecrosis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BEVACIZUMAB; CISPLATIN; EPIRUBICIN; METRONIDAZOLE;

ADULT; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CASE REPORT; CERVICAL SPINE; HUMAN; JAW OSTEONECROSIS; MALE; MOUTH HYGIENE; PAROTID GLAND CARCINOMA; PELVIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RIB;

EID: 84868022117     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201202500328     Document Type: Article

References (11)

1. Kim KJ, Li B, Houck K, Winer J, Ferrara N. The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992; 7: 53-64.
2. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-76.
3. Manegold C. Bevacizumab for the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther 2008; 8: 689-99.
4. Jonasch E, LaI LS, Atkinson BJ, Byfield SD, Miller LA, Pagliaro LC, Feng C, Tannir NM. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. BJU Int 2011; 107: 741-8.
5. Estilo CL, Former M, Farooki A, Carlson D, Bohle G 3rd, Huryn JM. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008; 26: 4037-8.
6. Greuter S, Schmid F, Ruhstaller T, Thuerlimann B. Bevacizumab-associated ostenecrosis of the jaw. Ann Oncol 2008; 19: 2091-2.
7. Serra E, Paolantonio M, Spoto G, Mastrangelo F, Tetè S, Dolci M. Bevacizumab-related osteneocrosis of the jaw. Int J Immunopathol Pharmacol 2009; 22: 1121-3.
8. Dişel U, Besen AA, Ozyilkan O, Er E, Canpolat T. A case report of bevacizumab-related osteonecrosis of the jaw: Old problem, new culprit. Oral Oncol 2012; 48: e2-3.
9. Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 2007; 86: 1013-21.
10. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. Task force on bisphosphonaterelated osteonecrosis of the jaws, American association of oral and maxillofacial surgeons. American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J 2009; 35: 119-30.
11. Reid IR, Cundy T: Osteonecrosis of the jaw. Skeletal Radiol 2009; 38: 5-9.